Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.

Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too. 

Research shows bringing trials to community oncology centers remains a daunting task, but Verily and OneOncology aim to help with new clinical trial management software. In other trial news, MindBio’s LSD goes into Phase II; Erasca starts tumor agnostic program; the Project to Accelerate New Treatments for Tuberculosis launched an international study investigating new combinations; and more.

Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.